bevacizumab-maly

CHEBI:CHEBI_756023

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
2599052
product_type
HUMAN PRESCRIPTION DRUG
listing_expiration_date
20251231
dosage_form
INJECTION, SOLUTION
route
INTRAVENOUS
marketing_start_date
20220415
package_marketing_start_date
20220415
marketing_category
BLA
nui
N0000178291
pharm_class_epc
Vascular Endothelial Growth Factor Inhibitor [EPC]
pharm_class
Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
pharm_class_moa
Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
labeler_name
Amneal Pharmaceuticals LLC
manufacturer_name
Amneal Pharmaceuticals LLC
active_ingredient_name
BEVACIZUMAB
active_ingredient_strength
400 mg/16mL
unii
2S9ZZM9Q9V
generic_name
bevacizumab-maly
brand_name
ALYMSYS
brand_name_base
ALYMSYS
product_ndc
70121-1755
application_number
BLA761231
spl_id
eef75c43-bea4-4772-a341-c33ab0c5216a
package_ndc
70121-1755-7
package_description
10 VIAL in 1 CARTON (70121-1755-7) / 16 mL in 1 VIAL
spl_set_id
6b4040a2-a5c5-4ff0-ab45-935d7e49cf78
upc
0370121175414
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class